title: Reversal of 'refractory septic shock' by infusion of amrinone and angiotensin II in an anthracycline-treated patient.
abstract: A 53-year-old granulocytopenic woman with malignant lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, including doxorubicin (Adriamycin) and autologues bone marrow transplantation, presented in the clinical state of "refractory septic shock" caused by Escherichia coli. Despite inotropic treatment with dopamine, dobutamine, and norepinephrine infusion, the patient's condition did not improve, but during treatment with amrinone and angiotensin II infusion, the septic shock was reversed. The patient was monitored with a pulmonary artery catheter and underwent repeated echocardiographic examinations. Antibiotic treatment with thienamycin and floxacillin was given. The initial reduction in cardiac performance in this patient may be explained by a state of true down-regulation of the myocardial beta-receptors. Apparently these beta-receptors were bypassed via the enzymatic action of amrinone upon cyclic monoadenosine phosphate. This is, to our knowledge, the first doxorubicin-treated patient with septic shock refractory to conventional vasopressor therapy whose condition reversed by inotropic treatment with amrinone and angiotensin II. This treatment may prove to be an alternative choice for patients developing "refractory septic shock" unresponsive to treatment with norepinephrine, dobutamine, and dopamine.
authors: Department of Anesthesia, Rigshospitalet, University of Copenhagen, Denmark.
authors: J
authors: J
authors: Ryding
authors: L
authors: L
authors: Heslet
authors: T
authors: T
authors: Hartvig
authors: V
authors: V
authors: Jønsson
mesh_terms: D000676:Amrinone / Q000008:administration & dosage* / Q000627:therapeutic use; D000804:Angiotensin II / Q000008:administration & dosage* / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004927:Escherichia coli Infections / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D012772:Shock, Septic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000804:Angiotensin II; D004317:Doxorubicin; D000676:Amrinone